SHENZHEN, China, Sept. 10, 2015 /PRNewswire/ -- Mindray Medical International Limited ("Mindray") (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that the board of directors of the Company (the "Board") has received a revised non-binding proposal, dated September 10, 2015, from Mr. Li Xiting, its Executive Chairman of the Board, President and Co-CEO, Mr. Xu Hang, its Chairman of the Board, and Mr. Cheng Minghe, its Co-CEO and Chief Strategic Officer (collectively, the "Buyer Group"), to acquire all of the outstanding shares of the Company not already owned by the Buyer Group for US$27 per American Depositary Share ("ADS", each ADS representing one ordinary share) or US$27 per ordinary share in cash, subject to certain conditions. A copy of the proposal letter is attached to this press release.
The special committee of the Board (the "Special Committee"), formed to consider the original proposal by the Buyer Group, is evaluating this revised proposal with the assistance of its financial and legal advisors. The Special Committee cautions the Company's shareholders and others considering trading in the Company's securities that no decision has been made by the Special Committee or the Board with respect to the revised proposal. There can be no assurance that any definitive offer will be made, any agreement will be executed or that this or any other transaction will be approved or consummated.
About Mindray
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters inShenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.